Cargando…

Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment

Fibroblast growth factor receptor 3 (FGFR3) alters frequently across various cancer types and is a common therapeutic target in bladder urothelial carcinoma (BLCA) with FGFR3 variants. Although emerging evidence supports the role of FGFR3 in individual cancer types, no pan-cancer analysis is availab...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Juanni, Hu, Kuan, Huang, Jinzhou, Zhou, Lei, Yan, Yuanliang, Xu, Zhijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266346/
https://www.ncbi.nlm.nih.gov/pubmed/34160364
http://dx.doi.org/10.18632/aging.203175
_version_ 1783719927484514304
author Li, Juanni
Hu, Kuan
Huang, Jinzhou
Zhou, Lei
Yan, Yuanliang
Xu, Zhijie
author_facet Li, Juanni
Hu, Kuan
Huang, Jinzhou
Zhou, Lei
Yan, Yuanliang
Xu, Zhijie
author_sort Li, Juanni
collection PubMed
description Fibroblast growth factor receptor 3 (FGFR3) alters frequently across various cancer types and is a common therapeutic target in bladder urothelial carcinoma (BLCA) with FGFR3 variants. Although emerging evidence supports the role of FGFR3 in individual cancer types, no pan-cancer analysis is available. In this work, we used the open comprehensive datasets, covering a total of 10,953 patients with 10,967 samples across 32 TCGA cancer types, to identify the full alteration spectrum of FGFR3. FGFR3 abnormal expression, methylation patterns, alteration frequency, mutation location distribution, functional impact, and prognostic implications differed greatly from cancer to cancer. The overall alteration frequency of FGFR3 was relatively low in all cancers. Targetable mutations were mainly detected in BLCA, and S249C, Y373C, G370C, and R248C were hotspot mutations that could be targeted by an FDA approved erdafitinib. Genetic fusions were mainly observed in glioma, followed by BLCA. FGFR3-TACC3 was the most common fusion type which was proposed as novel therapeutic targets in glioma and was targetable with erdafitinib in BLCA. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) were two lung cancer subtypes, FGFR3 fusion and hotspot mutation like S249C were observed more commonly in LUSC but not in LUAD. DNA methylation was correlated with the expression of FGFR3 and its downstream genes in some tumors. FGFG3 abnormal expression and alterations exhibited clinical correlations with patient prognosis in several tumors. This work exhibited the full alteration spectrum of FGFR3 and indicated several new clues for their application as potential therapeutic targets and prognostic indicators.
format Online
Article
Text
id pubmed-8266346
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-82663462021-07-09 Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment Li, Juanni Hu, Kuan Huang, Jinzhou Zhou, Lei Yan, Yuanliang Xu, Zhijie Aging (Albany NY) Research Paper Fibroblast growth factor receptor 3 (FGFR3) alters frequently across various cancer types and is a common therapeutic target in bladder urothelial carcinoma (BLCA) with FGFR3 variants. Although emerging evidence supports the role of FGFR3 in individual cancer types, no pan-cancer analysis is available. In this work, we used the open comprehensive datasets, covering a total of 10,953 patients with 10,967 samples across 32 TCGA cancer types, to identify the full alteration spectrum of FGFR3. FGFR3 abnormal expression, methylation patterns, alteration frequency, mutation location distribution, functional impact, and prognostic implications differed greatly from cancer to cancer. The overall alteration frequency of FGFR3 was relatively low in all cancers. Targetable mutations were mainly detected in BLCA, and S249C, Y373C, G370C, and R248C were hotspot mutations that could be targeted by an FDA approved erdafitinib. Genetic fusions were mainly observed in glioma, followed by BLCA. FGFR3-TACC3 was the most common fusion type which was proposed as novel therapeutic targets in glioma and was targetable with erdafitinib in BLCA. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) were two lung cancer subtypes, FGFR3 fusion and hotspot mutation like S249C were observed more commonly in LUSC but not in LUAD. DNA methylation was correlated with the expression of FGFR3 and its downstream genes in some tumors. FGFG3 abnormal expression and alterations exhibited clinical correlations with patient prognosis in several tumors. This work exhibited the full alteration spectrum of FGFR3 and indicated several new clues for their application as potential therapeutic targets and prognostic indicators. Impact Journals 2021-06-23 /pmc/articles/PMC8266346/ /pubmed/34160364 http://dx.doi.org/10.18632/aging.203175 Text en Copyright: © 2021 Li et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Li, Juanni
Hu, Kuan
Huang, Jinzhou
Zhou, Lei
Yan, Yuanliang
Xu, Zhijie
Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment
title Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment
title_full Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment
title_fullStr Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment
title_full_unstemmed Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment
title_short Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment
title_sort insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266346/
https://www.ncbi.nlm.nih.gov/pubmed/34160364
http://dx.doi.org/10.18632/aging.203175
work_keys_str_mv AT lijuanni insightsoffibroblastgrowthfactorreceptor3aberrationsinpancancerandtheirrolesinpotentialclinicaltreatment
AT hukuan insightsoffibroblastgrowthfactorreceptor3aberrationsinpancancerandtheirrolesinpotentialclinicaltreatment
AT huangjinzhou insightsoffibroblastgrowthfactorreceptor3aberrationsinpancancerandtheirrolesinpotentialclinicaltreatment
AT zhoulei insightsoffibroblastgrowthfactorreceptor3aberrationsinpancancerandtheirrolesinpotentialclinicaltreatment
AT yanyuanliang insightsoffibroblastgrowthfactorreceptor3aberrationsinpancancerandtheirrolesinpotentialclinicaltreatment
AT xuzhijie insightsoffibroblastgrowthfactorreceptor3aberrationsinpancancerandtheirrolesinpotentialclinicaltreatment